Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
280 participants
OBSERVATIONAL
2021-09-09
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Risk factors transmission cases
Human cases of monkeypox confirmed by PCR
blood samples
5 mL
Scabs and pus samples
if available
Risk factors transmission contacts and co-exposures
Human contact of confirmed monkeypox cases
blood samples
5 mL
Serological follow up cases
Human cases of monkeypox confirmed by PCR from Lobaye region
blood samples
5 mL
Scabs and pus samples
if available
Serological follow up contacts and co-exposures
Human contact of confirmed monkeypox cases from Lobaye region adjusted for age, month of the year and village of origin
blood samples
5 mL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood samples
5 mL
Scabs and pus samples
if available
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Health care personnel (paramedics, nurses, doctors) who work or have worked in affected villages
* Traditional healers, diviners
* Members of villages affected by past monkeypox epidemics
Exclusion Criteria
* refusal to participate
* inability to obtain consent
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Pasteur de Bangui
AMBIG
Institut Pasteur
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut Pasteur Bangui
Bangui, , Central African Republic
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Besombes C, Gonofio E, Konamna X, Selekon B, Grant R, Gessain A, Berthet N, Manuguerra JC, Fontanet A, Nakoune E. Intrafamily Transmission of Monkeypox Virus, Central African Republic, 2018. Emerg Infect Dis. 2019 Aug;25(8):1602-1604. doi: 10.3201/eid2508.190112. Epub 2019 Aug 17.
Berthet N, Descorps-Declere S, Besombes C, Curaudeau M, Nkili Meyong AA, Selekon B, Labouba I, Gonofio EC, Ouilibona RS, Simo Tchetgna HD, Feher M, Fontanet A, Kazanji M, Manuguerra JC, Hassanin A, Gessain A, Nakoune E. Genomic history of human monkey pox infections in the Central African Republic between 2001 and 2018. Sci Rep. 2021 Jun 22;11(1):13085. doi: 10.1038/s41598-021-92315-8.
Related Links
Access external resources that provide additional context or updates about the study.
Institut Pasteur Afripox
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-047
Identifier Type: -
Identifier Source: org_study_id